HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC Topicals After Bite, Itch Eraser Are Irritants To US FDA Monograph, GMP Regulations

Executive Summary

Adventure Ready Brands is the second small firm warned recently by FDA about manufacturing and marketing products labeled as nonprescription drugs but noncompliant with relevant OTC drug monographs and about GMP violations.

You may also be interested in...



US FDA Warns Foreign Manufacturers Of OTC Analgesics For Monograph Non-Compliance

Malaysia-based Furley Bioextracts and Honduras-based Laboratorio Pharma International receive warning letters from the US FDA following import alerts in May and June for marketing products as OTC analgesic drugs without complying with controlling monograph conditions.

Eosera Expands Into Nasal Care While Linking App For Live Video With Latest Ear Care Line Extension

Eosera is launching two devices for cleaning and taking pictures of ears, while also entering the nasal care segment with an irrigation product that uses gravity to flush saline through the nostrils.

OTC Ear Care Firm Eosera Gets Earful From US FDA On Pain And Itch Remedies, GMP Compliance

Eosera has removed its Ear Pain MD and Ear Itch MD products from e-commerce pages on its website following FDA's warning letter. The warning identifying the pain and itch products as unapproved new drugs also states that a January inspection of the firm’s facility found GMP violations. 

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS150298

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel